Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
Allison
J
J
Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Australia.
Seino
K
K
Yagita
H
H
D000818:Animals; D053222:Fas Ligand Protein; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D051379:Mice; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation / Q000276:immunology / Q000473:pathology; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000378:metabolism*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins